Table 12 Expression levels of miRNAs targeting i.a. TYMS mRNA in cancer
From: MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy
miRNA | Level†| Cancers‡ | References |
|---|---|---|---|
miR-375-3p | Down | CRC tissues, Caco2, HCT116, SW480, HT29 cell lines | Xu et al. (2020b) |
| Â | Down | CRC tissues | Liu et al. (2020a) |
| Â | Down | CRC tissues: 5FU-resistant vs sensitive | Chen et al. (2020b) |
| Â | Down | CRC tissues, Caco2, HCT116, SW480, HT29, SW620 lines | Xu et al. (2019a) |
| Â | Down | HCT8/FU (5FU resistant) vs HCT8 (parental sensitive) | Xu et al. (2019a) |
| Â | Down | HCT116/FU (5FU resistant) vs HCT116 (sensitive) | Xu et al. (2019a) |
| Â | Down | CRC tissues: 5FU-resistant vs sensitive | Xu et al. (2019a) |
| Â | Down | in serum of CRC patients | Huang et al. (2020a) |
| Â | Down | CRC tissues, HCT116, SW480, HT29, SW620 cell lines | Xu et al. (2016a) |
| Â | Down | CRC tissues, SW480, HT29, SW620, HCT116, HCT8 | Mao et al. (2016) |
|  | Down | CRC stage III–IV vs stage I–II | Mao et al. (2016) |
| Â | Down | CRC tissues | Wang et al. (2014b) |
| Â | Down | CRC tissues, HT29, SW620, HCT116 cell lines | Dai et al. (2012) |
| Â | Down | GC tissues and three cell lines | Liu et al. (2019b) |
| Â | Down | GC tissues and two cell lines | Huang et al. (2019b) |
| Â | Down | GC tissues and ten cell lines | Kang et al. (2018) |
| Â | Down | GC tissues | Chen et al. (2017d) |
| Â | Down | GC tissues | Yuan et al. (2018) |
| Â | Down | ESCC tissues and four cell lines | Li et al. (2021a) |
| Â | Down | ESCC tissues | Cheng et al. (2020b) |
| Â | Down | ESCC tissues and two cell lines | Xu et al. (2019b) |
| Â | Down | ESCC tissues and one cell line | Hu et al. (2017b) |
| Â | Down | ESCC tissues and cell lines | Kong et al. (2012) |
| Â | Down | LSCC and three cell lines | Chang et al. (2020) |
| Â | Up | LSCC: III/IV vs I/II TNM stage | Wu et al. (2016) |
|  | Down | LSCC: III–IV vs I–II clinical stage | Guo et al. (2016) |
| Â | Down | LSCC tissues and two cell lines | Wang et al. (2016b) |
|  | Down | LSCC tissues, UICC advanced III–IV vs early I–II stage | Luo et al. (2014) |
| Â | Down | OSCC tissues and four cell lines | Tong et al. (2021) |
| Â | Down | OSCC tissues and four cell lines | Wu et al. (2017) |
| Â | Down | OSCC tissues, with vs without lymph node metastasis | Zhang et al. (2017) |
| Â | Down | OSCC tissues | Shi et al. (2015) |
| Â | Down | NSCLC tissues and A549, H1299 cell lines | Jin et al. (2021) |
| Â | Down | NSCLC tissues, stages IV vs III vs II vs I | Chen et al. (2017f) |
| Â | Down | NSCLC (SqCLC) tissues, stage III vs II | Chen et al. (2017g) |
| Â | Up | BRCA tissues (luminal A/B, HER2+), three cell lines | Guan et al. (2021) |
| Â | Down | HCC tissues and four cell lines (i.a. Huh7) | Xu et al. (2021) |
| Â | Down | HCC tissues and five cell lines | Li et al. (2021b) |
| Â | Down | HCC tissues and four cell lines (i.a. Huh7) | Li et al. (2021c) |
| Â | Down | HCC tissues and five cell lines (i.a. Huh7) | Li et al. (2018b) |
| Â | Down | HCC tissues | He et al. (2012) |
| Â | Down | HCC tissues | Liu et al. (2010) |
| Â | Down | PDAC tissues and two cell lines (PANC-1, SW 1990) | Yonemori et al. (2017) |
| Â | Up | PDAC tissues and ten cell lines (i.a. PANC-1, SW 1990) | Yang et al. (2016) |
| Â | Down | PDAC tissues | Zhou et al. (2014b) |
| Â | Down | PDAC tissues | Song et al. (2013a) |
| Â | Down | PDAC tissues and four cell lines (i.a. PANC-1, SW 1990) | Song et al. (2013b) |
| Â | Down | CeCa tissues (stage I-IV) and four cell lines | Cao et al. (2021) |
| Â | Up | CeCa: PTX-resistant vs pre-chemotherapy tissues | Shen et al. (2013) |
| Â | Down | CeCa tissues, FIGO stage IIA vs IB1/IB2 | Wang et al. (2011) |
| Â | Down | OVCA tissues and four cell lines | Shu et al. (2021) |
| Â | Up | PCa tissues | Porzycki et al. (2018) |